Yale University
yale.eduTotal trials
1,731
Active
386
Phase 3
83
Total enrollment
3,771,094
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 190 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Empagliflozin 10 MG | — | — | — | 3 | |||
| Buprenorphine | — | — | 15 | ||||
| Methadone | — | — | 5 | ||||
| Aldosterone | — | — | — | — | 2 | ||
| Spironolactone 25mg | — | — | — | — | — | 1 | |
| Beta blocker | — | — | — | — | — | 1 | |
| Calcium channel blocker | — | — | — | — | — | 1 | |
| Bexagliflozin 20 mg | — | — | — | — | — | 1 | |
| Exogenous oxytocin intravenous infusion without nipple stimulation. | — | — | — | — | — | 1 | |
| Desogestrel / Ethinyl Estradiol Pill | — | — | — | — | — | 1 | |
| Empagliflozin 25 mg vs Placebo | — | — | — | — | — | 1 | |
| Artemether-lumefantrine | — | — | — | — | — | 1 | |
| artesunate-amodiaquine | — | — | — | — | — | 1 | |
| Athena strategy | — | — | — | — | — | 1 | |
| Spravato | — | — | — | — | 2 | ||
| Lisdexamfetamine Dimesylate | — | — | — | — | — | 3 | |
| Aspirin | — | — | — | 3 | |||
| Enoxaparin | — | — | — | — | 2 | ||
| Elagolix 200 MG | — | — | — | — | — | 2 | |
| Apixaban | — | — | — | — | — | 1 | |
| Naltrexone Pill | — | — | — | — | — | 1 | |
| Gabapentin Pill | — | — | — | — | — | 1 | |
| Anakinra | — | — | — | — | — | 1 | |
| Tocilizumab | — | — | — | — | — | 1 | |
| Naltrexone and Bupropion medication | — | — | — | — | — | 1 | |
| Racemic ketamine | — | — | — | — | — | 1 | |
| Naltrexone and Bupropion (NB) medication | — | — | — | — | — | 1 | |
| Green Tea Extract | — | — | — | — | — | 1 | |
| Naltrexone | — | 19 | |||||
| Eszopiclone | — | — | — | 3 | |||
| Naltrexone and Bupropion Combination | — | — | — | — | 2 | ||
| THC | — | — | — | 8 | |||
| Pembrolizumab | — | — | — | — | 7 | ||
| Sacituzumab Govitecan | — | — | — | — | — | 4 | |
| Ketamine | 23 | ||||||
| Varenicline | — | 17 | |||||
| Nivolumab | — | — | — | — | 4 | ||
| Naltrexone hydrochloride | — | — | — | — | 2 | ||
| Semaglutide Pen Injector | — | — | — | — | — | 2 | |
| Bupivacaine-Liposomal Bupivacaine | — | — | — | — | — | 2 |
150 more active programs hidden
Next readouts
- 2018-08-10
- 2021-07-08
- 2025-06-30
- 2025-11
- 2025-12
- 2025-12
- 2025-12
- 2025-12-01
- 2025-12-01
- 2025-12-12
Top conditions
- Schizophrenia47
- Obesity46
- Depression37
- Nicotine Dependence35
- Alcohol Use Disorder31
- Smoking30
- Opioid Use Disorder30
- HIV29
Frequently asked questions about Yale University
- How many clinical trials does Yale University have on ClinicalTrials.gov?
- Yale University is listed as the lead sponsor on 1,731 clinical trials in ClinicalTrials.gov, 386 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Yale University's trials are in Phase 3?
- 83 of Yale University's trials are in Phase 3, spread across 190 active drug programs.
- What therapeutic areas does Yale University focus on?
- Yale University's most-studied conditions on ClinicalTrials.gov are Schizophrenia, Obesity, Depression, Nicotine Dependence, Alcohol Use Disorder.
- When are Yale University's next clinical trial readouts?
- Yale University has 10 upcoming primary-completion readouts tracked here; the soonest is “Cannabinoids, Learning, and Memory”, expected around 2018-08-10.